Nuclear imaging for immune cell tracking in vivo – Comparison of various cell labeling methods and their application

Kiraga, Łukasz; Kucharzewska, Paulina; Paisey, Stephen J.; Cheda, Łukasz; Domańska, Anita; Rogulski, Z.; Rygiel, Tomasz P.; Boffi, Alberto; Król, Magdalena

doi:10.1016/j.ccr.2021.214008

Cited by 16 publications

(8 citation statements)

References 229 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, lipophilic radiopharmaceuticals (ie, 111 In/ 89 Zr-oxine, 99m Tc-HMPAO, 64 Cu-PTSM) cross the cell membrane by diffusion, synthetic structures such as 64 Cu-PEI are endo/ phagocytosed, and labeled antibodies target immune cells' surface receptors. 8,9 However, the intracellular metabolism and efflux of radiotracers from labeled cells can lead to image misinterpretation. Radiationinduced cytotoxicity and loss of radioactivity during cell division and proliferation can complicate the imaging readout.…”

Section: Direct Immune Cell Labelingmentioning

confidence: 99%

“…Other genes, such as hSSTR2 (human somatostatin receptor subtype 2), have also been examined for immune cell tracking. 8,10 Unlike direct cell labeling strategy, reporter genes allow repeated imaging while the gene is expressed. While characterized in clinical stem cell therapies, safety and regulatory issues linger, and the method remains amenable for exogenous cells only, such that natural immune cell kinetics are not directly interrogated.…”

Section: Reporter Gene Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Nuclear Methods for Immune Cell Imaging: Bridging Molecular Imaging and Individualized Medicine

Heo

Diekmann

Thackeray

et al. 2023

Circ: Cardiovascular Imaging

View full text Add to dashboard Cite

Inflammation is a key mechanistic contributor to the progression of cardiovascular disease, from atherosclerosis through ischemic injury and overt heart failure. Recent evidence has identified specific roles of immune cell subpopulations in cardiac pathogenesis that diverges between individual patients. Nuclear imaging approaches facilitate noninvasive and serial quantification of inflammation severity, offering the opportunity to predict eventual outcome, stratify patient risk, and guide novel targeted molecular therapies against specific leukocyte subpopulations. Here, we will discuss the established and emerging nuclear imaging methods to label and track exogenous and endogenous immune cells, with a particular focus on clinical situations in which targeted molecular inflammation imaging would be advantageous. The expanding options for imaging inflammation provide the foundation to bridge between molecular imaging and individual therapy.

show abstract

Section: Direct Immune Cell Labelingmentioning

confidence: 99%

Section: Reporter Gene Imagingmentioning

confidence: 99%

Nuclear Methods for Immune Cell Imaging: Bridging Molecular Imaging and Individualized Medicine

Heo

Diekmann

Thackeray

et al. 2023

Circ: Cardiovascular Imaging

View full text Add to dashboard Cite

show abstract

“…The use of nuclear imaging to track dendritic cells dynamically involves detecting radioisotope-labeled cells. There are two main cell labeling techniques for nuclear imaging: direct cell labeling using radiotracers or indirect cell labeling involving the expression of imaging reporter genes in target cells …”

Section: Dc-based Cancer Vaccinesmentioning

confidence: 99%

Emerging Strategies of Engineering and Tracking Dendritic Cells for Cancer Immunotherapy

Gao

Wang

Cui

et al. 2022

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Dendritic cells (DCs), a kind of specialized immune cells, play key roles in antitumor immune response and promotion of innate and adaptive immune responses. Recently, many strategies have been developed to utilize DCs in cancer therapy, such as delivering antigens and adjuvants to DCs and using scaffold to recruit and activate DCs. Here we outline how different DC subsets influence antitumor immunity, summarize the FDA-approved vaccines and cancer vaccines under clinical trials, discuss the strategies for engineering DCs and noninvasive tracking of DCs to improve antitumor immunotherapy, and reveal the potential of artificial neural networks for the design of DC based vaccines.

show abstract

“…In addition, PET and SPECT show high compatibility with other imaging modalities, such as optical imaging, computed tomography (CT), or MRI, which provide multimodal information from molecular, cellular, and anatomical scales. The overview of nuclear imaging with its applications in tracking immune cells in vivo has been reviewed previously, [28,29] but most focused on labeling techniques rather than the behaviors of CAR T cells in vivo. Here, we will summarize the progress of PET and SPECT in monitoring CAR T immunotherapy in three aspects: tumor accessibility, intratumoral viability, and cytotoxic function of cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Nuclear Imaging of CAR T Immunotherapy to Solid Tumors: In Terms of Biodistribution, Viability, and Cytotoxic Effect

et al. 2023

View full text Add to dashboard Cite

Immunotherapy has become a mainstay of cancer therapy. Since chimeric antigen receptor (CAR) T immunotherapy achieves unprecedented success in curing hematological malignancies, the possibility of it revolutionizing the paradigm of solid tumors has aroused increasing attention. However, the restricted accessibility to tumor parenchyma, the immunosuppressive tumor microenvironment, and antigen heterogeneity of solid tumors make it difficult to replicate its success. Therefore, dynamic evaluation of CAR T cells’ tumor accessibility, intratumoral viability, and anti‐tumor cytotoxicity is necessary to facilitate its translation to solid tumors. Besides, real‐timely imaging above events in vivo can help evaluate therapeutic responses and optimize CAR T immunotherapy for solid tumors. Nuclear imaging, including positron emission tomography (PET) and single‐photon emission computed tomography (SPECT) imaging, is frequently applied for evaluating adoptive cell therapies owing to its excellent sensitivity, high tissue penetration, and great translation potential. In addition, quantitative analysis can be performed in dynamic and noninvasive patterns. This review focuses on recent advances in PET/SPECT technologies and imaging probes in monitoring CAR T cells’ migration, viability, and cytotoxicity to solid tumors post‐administration. Prospects of what should be done in the next stage to promote CAR T therapy's application in solid tumors are also discussed.

show abstract

Nuclear imaging for immune cell tracking in vivo – Comparison of various cell labeling methods and their application

Cited by 16 publications

References 229 publications

Nuclear Methods for Immune Cell Imaging: Bridging Molecular Imaging and Individualized Medicine

Nuclear Methods for Immune Cell Imaging: Bridging Molecular Imaging and Individualized Medicine

Emerging Strategies of Engineering and Tracking Dendritic Cells for Cancer Immunotherapy

Nuclear Imaging of CAR T Immunotherapy to Solid Tumors: In Terms of Biodistribution, Viability, and Cytotoxic Effect

Contact Info

Product

Resources

About